Natural Cycles, a Stockholm, Sweden-based women’s health company that developed a birth control app, raised $55M in Series C funding.
The round was led by Lauxera Capital Partners, with participation from Point72 Private Investments and a revolving debt facility from J.P. Morgan. Investors also included EQT Ventures, Samsung Ventures, Heartcore Capital, Headline, and Bonnier Ventures. As part of the investment, Samuel Levy, founding partner of Lauxera Capital Partners, will join Natural Cycles’ Board of Directors.
The company intends to use the funds to invest in commercial acceleration, new product development, and healthcare reimbursement automation.
Founded in 2013 by Dr. Elina Berglund Scherwitzl and Dr. Raoul Scherwitzl, Natural Cycles provides a direct-to-consumer contraceptive app that has been used by more than three million users worldwide. The NC° app is empowered by an algorithm that uses body temperature to determine each user’s daily fertility status. Users can manually take their body temperature with a thermometer or sync overnight temperature trend data from an Oura Ring or Apple Watch when they wake up. The app was cleared by regulators in the United States (FDA), Europe (TÜV SÜD), Canada (Health Canada), Australia (TGA), Singapore (HSA), and South Korea (MFDS).
Earlier this month, the company launched NC° Postpartum, an innovative experience within the Natural Cycles app specifically tailored to help guide new moms recovering physically and mentally from childbirth. NC° Postpartum builds on the other three modes already available within the Natural Cycles app – NC° Birth Control, NC° Plan Pregnancy, and NC° Follow Pregnancy – providing users with support throughout their fertility journey.
FinSMEs
30/05/2024